Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Income from Continuing Operations: 2021-2025

Historic Income from Continuing Operations for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Sep 2025 value amounting to $7.4 million.

  • Arcutis Biotherapeutics' Income from Continuing Operations rose 117.84% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$44.3 million, marking a year-over-year increase of 77.33%. This contributed to the annual value of -$140.0 million for FY2024, which is 46.58% up from last year.
  • According to the latest figures from Q3 2025, Arcutis Biotherapeutics' Income from Continuing Operations is $7.4 million, which was up 146.64% from -$15.9 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' 5-year Income from Continuing Operations high stood at $7.4 million for Q3 2025, and its period low was -$107.7 million during Q3 2022.
  • For the 3-year period, Arcutis Biotherapeutics' Income from Continuing Operations averaged around -$39.6 million, with its median value being -$41.5 million (2024).
  • In the last 5 years, Arcutis Biotherapeutics' Income from Continuing Operations slumped by 88.70% in 2022 and then soared by 117.84% in 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' Income from Continuing Operations (Quarterly) stood at -$71.3 million in 2021, then fell by 1.03% to -$72.0 million in 2022, then rose by 7.96% to -$66.3 million in 2023, then skyrocketed by 83.72% to -$10.8 million in 2024, then soared by 117.84% to $7.4 million in 2025.
  • Its Income from Continuing Operations stands at $7.4 million for Q3 2025, versus -$15.9 million for Q2 2025 and -$25.1 million for Q1 2025.